Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any retinitis pigmentosa in which the cause of the disease is a mutation in the PCARE gene.
Features include: Bone spicule pigmentation of the retina, Fundus atrophy, Nyctalopia, and Visual impairment and 3 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 2 | Visual impairment, Attenuation of retinal blood vessels |
Bones and joints |
PCARE function has not been fully characterized.
Retinitis pigmentosa 54 is associated with mutations in the PCARE gene on chromosome 2.
Genetic testing for PCARE is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for retinitis pigmentosa 54 has been reported in the published literature.
No clinical trials have been registered for retinitis pigmentosa 54.
43 publications have been identified in PubMed for retinitis pigmentosa 54. Research spans Epidemiology / Natural History (40%), Basic Science / Preclinical (19%), and Diagnostic / Biomarker (14%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 17 | 40% |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 12:31 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
1 |
Bone spicule pigmentation of the retina |
Muscles | 1 | Fundus atrophy |
Laboratory research
8 |
19% |
Testing and diagnosis research | 6 | 14% |
Clinical study results | 5 | 12% |
Patient case studies | 4 | 9% |
New treatment approaches | 2 | 5% |
Research summaries | 1 | 2% |
Gao P (2026). [PMID: 42023663](https://pubmed.ncbi.nlm.nih.gov/42023663/). *Invest Ophthalmol Vis Sci*. [Gene Therapy / Novel Therapeutics]
Parekh BJ (2026). [PMID: 41760091](https://pubmed.ncbi.nlm.nih.gov/41760091/). *Clin Exp Ophthalmol*. [Epidemiology / Natural History]
Hühne T (2026). [PMID: 40903014](https://pubmed.ncbi.nlm.nih.gov/40903014/). *The Journal of clinical endocrinology and metabolism*. [Diagnostic / Biomarker]
Almansa-García AC (2026). [PMID: 41514281](https://pubmed.ncbi.nlm.nih.gov/41514281/). *BMC medicine*. [Epidemiology / Natural History]
Tang W (2026). [PMID: 41729366](https://pubmed.ncbi.nlm.nih.gov/41729366/). *Int Ophthalmol*. [Clinical Trial Publication]
Durno NS (2026). [PMID: 41686418](https://pubmed.ncbi.nlm.nih.gov/41686418/). *Advances in therapy*. [Basic Science / Preclinical]
Wang Y (2026). [PMID: 41125404](https://pubmed.ncbi.nlm.nih.gov/41125404/). *Clinical & experimental ophthalmology*. [Basic Science / Preclinical]
Yang J (2026). [PMID: 41773775](https://pubmed.ncbi.nlm.nih.gov/41773775/). *Translational vision science & technology*. [Review / Meta-Analysis]
Gregory-Evans CY (2026). [PMID: 41539649](https://pubmed.ncbi.nlm.nih.gov/41539649/). *Can J Ophthalmol*. [Basic Science / Preclinical]
Beaulieu C (2026). [PMID: 41954904](https://pubmed.ncbi.nlm.nih.gov/41954904/). *JAMA ophthalmology*. [Basic Science / Preclinical]